Objective: Signaling through Prostaglandin E3 Receptor (EP3), a G protein-coupled receptor for E series prostaglandins such as prostaglandin E2 (PGE2), has been linked to the beta-cell dysfunction and loss of beta-cell mass in type 2 diabetes (T2D). In the beta-cell, EP3 is specifically coupled to the unique cAMP-inhibitory G protein, Gz. Divergent effects of EP3 agonists and antagonists or Gαz loss on beta-cell function, replication, and survival depending on whether islets are isolated from mice or humans in the lean and healthy, type 1 diabetic, or T2D state suggest a divergence in biological effects downstream of EP3/Gαz dependent on the physiological milieu in which the islets reside. Methods: We determined the expression of a number of genes in the EP3/Gαz signaling pathway; PGE2 production pathway; and the beta-cell metabolic, proliferative, and survival responses to insulin resistance and its corresponding metabolic and inflammatory derangements in a panel of 80 islet preparations from non-diabetic human organ donors spanning a BMI range of approximately 20-45. In a subset of islet preparations, we also performed glucose-stimulated insulin secretion assays with and without the addition of an EP3 agonist, L798,106, and a glucagon-like peptide 1 receptor agonist, exendin-4, allowing us to compare the gene expression profile of each islet preparation with its (1) total islet insulin content (2), functional responses to glucose and incretin hormones, and (3) intrinsic influence of endogenous EP3 signaling in regulating these functional responses. We also transduced two independent islet preparations from three human organ donors with adenoviruses encoding human Gαz or a GFP control in order to determine the impact of Gαz hyperactivity (a mimic of the T2D state) on human islet insulin content and functional response to glucose. Results: In contrast to results from islets isolated from T2D mice and human organ donors, where PGE2-mediated EP3 signaling actively contributes to beta-cell dysfunction, PGE2 production and EP3 expression appeared positively associated with various measurements of functional beta-cell compensation. While Gαz mRNA expression was negatively associated with islet insulin content, that of each of the Gαz-sensitive adenylate cyclase (AC) isoforms were positively associated with BMI and cyclin A1 mRNA expression, suggesting increased expression of AC1, AC5, and AC6 is a compensatory mechanism to augment beta-cell mass. Human islets over-expressing Gαz via adenoviral transduction had reduced islet insulin content and secretion of insulin in response to stimulatory glucose as a percent of content, consistent with the effects of hyperactivation of Gαz by PGE2/EP3 signaling observed in islets exposed to the T2D physiological milieu. Conclusions: Our work sheds light on critical mechanisms in the human beta-cell compensatory response, before the progression to frank T2D.
Introduction
Fundamentally, Type 2 diabetes mellitus (T2D) results because of a failure of the insulinsecreting pancreatic beta-cells to compensate for peripheral insulin resistance. Obesity is the most common co-morbidity found in individuals with insulin resistance. While there exists debate about whether one condition precedes the other, the physiological changes that often occur in the obese, insulin-resistant state (e.g., systemic inflammation, dyslipidemia, hyperinsulinemia, mild hyperglycemia) simultaneously induce beta-cell stress and increase beta-cell workload, forcing the beta-cell to initiate a compensatory response in order to function, replicate, and survive. Whether the beta-cell can initiate and continue this adaptive program is the key determinant of the progression to T2D.
Cyclic AMP (cAMP) is a well-characterized potentiator of glucose-stimulated insulin secretion (GSIS) and promotes a number of proliferative and survival pathways in the beta-cell. Numerous changes in beta-cell cAMP homeostasis occur in a highly-compensating beta-cell, all with the central theme of increasing cAMP production, decreasing cAMP degradation, or promoting signaling through downstream effectors!!refs. Previous work from our laboratory revealed islets from Black and Tan Brachyury (BTBR) mice homozygous for the Leptin Ob mutation (BTBR-Ob), a strong genetic model of T2D, have a decreased ability to up-regulate cAMP production [1] . BTBR-Ob islets are also less responsive to agents that act through the cAMP-stimulatory glucagon-like peptide 1 receptor (GLP1R), suggesting a tonic brake on cAMP production that interferes with their ability to respond appropriately to glucose [1] . In contrast to GLP1R, Prostaglandin EP3 receptor (EP3), when constitutively active or bound by E-series prostaglandins such as prostaglandin E2 (PGE2: the most abundant natural ligand for EP3), negatively regulates cAMP production. Islets isolated from T2D mice and human organ donors express more EP3 and produce more PGE2 than islets isolated from non-diabetic controls [1] , and treating these islets with an EP3 receptor antagonist, L798,106, potentiates GSIS and restores their insulin secretory response to glucose and GLP1R agonists [1] .
In beta-cells, EP3 is coupled specifically to the unique inhibitory G protein, Gz [2, 3] . Islets from mice lacking the catalytic alpha-subunit of Gz (Gαz) constitutively produce more cAMP and secrete more insulin in response to glucose [2, [4] [5] [6] . Gαz-null mice are resistant to diabetes in a number of mouse models of the disease [2, 4, 5] . Gαz-null C57BL/6N mice are fully resistant to developing fasting hyperglycemia and glucose intolerance after a high-fat diet (HFD) feeding regimen-a model of pre-diabetes-due primarily to a synergistic effect of HFD feeding and the Gαz-null mutation on beta-cell proliferation [2] . While the GSIS response as a percent of islet insulin content is not as dysfunctional as that of wild-type HFD-fed mice, Gαz-null islets from HFD-fed mice secrete more insulin primarily because they are larger. This is in contrast to islets from lean, healthy, Gαz-null mice or in models of type 1 diabetes (T1D), which secrete more insulin as a percent of content. Gαz loss has no impact on food intake, body weight, insulin sensitivity, or the increase in plasma PGE2 metabolite levels induced by HFD feeding, and Gαz tissue distribution is quite limited, the protected phenotype of HFD-fed Gαz-null mice is best explained by a beta-cell-centric model.
Our previous studies using mouse models and pancreatic islets from T2D human organ donors, along with an extensive body of work from other investigators, suggest that both PGE2 production and EP3 expression are up-regulated by high glucose, pro-inflammatory cytokines, and/or free fatty acids, negatively influencing the islet function and mass. As GPCRs form the largest class of druggable targets in the human genome, we have previously proposed the EP3/Gαz interaction as a novel preventative or therapeutic target for T2D. Yet, a comprehensive analysis of the PGE2 production and EP3/Gαz signaling pathways and their correlation with betacell function and mass has never been completed in pancreatic islets of non-diabetic human donors; thus, whether targeting the EP3/Gαz interaction would prevent the progression from insulin resistance to T2D remains unclear.
In this work, we determined the mRNA expression of proteins involved in systemic inflammation, beta-cell compensation, PGE2 production, and EP3/Gαz signaling in two panels of pancreatic islets isolated from human organ donors (comprising 80 discrete individuals) and, in a sub-set of samples, correlated BMI and gene expression with islet insulin content and different measurements of glucose-stimulated and incretin-potentiated GSIS. We also transduced isolated human islets with an adenovirus expressing human Gαz as a mimic of the chronic up-regulation of EP3/Gαz signaling in the T2D state, quantifying the impact on islet insulin content and GSIS. Our results shed new light on the role of PGE2 production and Gαz signaling in the islet compensatory response to the pathophysiological conditions of obesity and insulin resistance and suggest a protective role of PGE2 production and EP3/Gαz signaling the beta-cell highly compensating for the peripheral insulin resistance, metabolic derangements, and inflammation often found in the obese state.
Materials & Methods

Materials and Reagents
Sodium chloride (S9888), potassium chloride (P3911), magnesium sulfate heptahydrate (M9397), potassium phosphate monobasic (P0662), sodium bicarbonate (S6014), HEPES (H3375), calcium chloride dehydrate (C3881), exendin-4 (E7144) and RIA-grade bovine serum albumin (A7888) were purchased from Sigma Aldrich (St. Louis, MO, USA). Anti-insulin antibodies (Insulin + Proinsulin Antibody, 10R-I136a; Insulin + Proinsulin Antibody, biotinylated, 61E-I136bBT) were from Fitzgerald Industries (Acton, MA, USA). The 10 ng/ml insulin standard (8013-K) and assay buffer (AB-PHK) were from Millipore. RPMI 1640 medium (11879-020: no glucose), penicillin/streptomycin (15070-063), and fetal bovine serum (12306C: qualified, heat inactivated, USDA-approved regions) were from Life Technologies (Carlsbad, CA, USA). Dextrose (D14-500) was from Fisher Scientific (Waltham, MA). The RNeasy Mini Kit and RNase-free DNase set were from Qiagen. High-Capacity cDNA Reverse Transcription Kit was from Applied Biosystems. FastStart Universal SYBR Green Master mix was from Roche (Indianapolis, IN).
Human islet preparations
Cultured human islets were obtained from the Integrated Islet Distribution Program (IIDP) and flash-frozen islet samples from BetaPro according to an approved IRB exemption protocol (UW 2012-0865). The islet preparations were collected in two sets of 40 preparations each: Set 1 was collected between October, 2010 and February, 2012. Islets in this set were only used for gene expression analyses. Set 2 was collected between March, 2013 and May 2015, and were used for both gene expression and insulin secretion assays (The unique identifiers for each islet preparation, along with age, sex, BMI, HbA1c, origin, islet isolation center, and assay the islets were used for are listed in Supplementary Tables 1 and 2 ). Most of the islet samples for quantitative PCR analysis were hand-picked and pelleted on the day of arrival and flash-frozen prior to RNA isolation. In other samples for qPCR and prior to all ex vivo insulin secretion assays, human islets were cultured for at 24 h in human islet medium (RPMI 1640 medium containing 8.4 mM glucose, supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin).
Ex vivo islet insulin secretion assays for BMI panel
Isolated human islets used in insulin secretion assays were obtained from the Integrated Islet Distribution Program (IIDP) between 2013 and 2015. The day before assay, islets were handpicked into 96-well V-bottom tissue culture plates and incubated overnight in RPMI growth medium to adhere islets to the bottom of the plate and single-islet GSIS assays performed with and without the addition of the indicated compounds to the stimulation medium, as previously described [7] . The secretion medium was removed via a multi-channel pipette, and islets were lysed in RLT buffer, resuspended, and secreted insulin and total islet insulin concentration quantified with in-house-generated insulin sandwich ELISA as described previously [7] . In general, secretion medium was diluted 1:20 and content medium diluted 1:200 in order for readings in the linear range of the assay.
Quantitative PCR assays
150-200 islets from each human islet preparation were washed with PBS and used to generate RNA samples via Qiagen RNeasy Mini Kit according to the manufacturer's protocol. Copy DNA (cDNA) was generated and relative qPCR performed via SYBR Green assay using primers validated to provide linear results upon increasing concentrations of cDNA template, as previously described [5] .
Human islet adenoviral transduction and insulin secretion assays
A bicistronic adenovirus expressing GFP and human Gαz was created by subcloning the Gαz coding sequence from a pcDNA 3.1 vector (Bloomsburg University cDNA Resource Center) into the VQpacAd-CMVK-NpA adenoviral entry vector (Viraquest Inc, North Liberty, IA). The entry vector was sent to Viraquest for recombination with a packaging vector bicistronically encoding an enhanced GFP protein (eGFP) and virus amplified and purified. The GFP control virus (VQAd-CMV-eGFP) was purchased from Viraquest. Viraquest viruses are confirmed to be viral E1Aprotein free.
On the day of receipt, 1000 islets and shipping media were transferred to a 50 ml conical tube and centrifuged at 800 x g for 2 min. Shipping media was aspirated and the islet pellet was resuspended in 20 ml of fresh islet culture and allowed to recover overnight in 10 cm petri dishes. Islets were pooled into a single 2.5 cm petri dish and hand-picked into a 15 ml conical tube containing 1 ml of a mild Accutase solution and incubated for 30 sec at 37 °C. The Accutase reaction was immediately blocked by addition of islet culture medium, and 300 islets were picked into triplicate petri dishes containing medium with 5 x 10 9 viral particles/ml (Experiment 1) or 5 x 10 12 viral particles/ml (Experiments 2 & 3) and cultured for 48 h prior to assay. Two dishes of islets per preparation was used for GSIS assays and one was used to generate cDNA for qPCR. GFP expression was confirmed by fluorescence microscopy and Gαz mRNA expression by qPCR.
On the day of assay, 10 islets per dish were picked into each well of a 12-well multi-well plate, in which each well contained 1 ml modified Krebs Ringer Bicarbonate Buffer (KRBB) containing 0.5% BSA and 1.7 mM glucose. Islets were incubated at 37°C and 5% CO2 for 45 min, then transferred into fresh 1.7 mM glucose KRBB and incubated for an additional 45 min. Finally, islets were picked into KRBB containing 1.7 mM glucose or 16.7 mM glucose and incubated again for 45 min. At the end of the assay, islets were picked into a conical tube containing 1 ml PBS, pelleted by pulsing in a microfuge, the PBS removed, and islets lysed in 1 ml of a detergent-based lysis buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, and 1% Triton-X. The stimulation buffer was saved for quantification of secreted insulin. Each treatment condition was performed in duplicate using two independent pools of islets from each donor, providing 6 total biological replicates. The insulin ELISA was performed as described above for the BMI study. GSIS% in 1.7 mM glucose, GSIS% in 16.7 mM glucose, and stimulation index were used in comparative analyses. The unique identifiers for the three islet preparations used in adenoviral infection experiments, along with age, sex, BMI, HbA1c, origin, islet isolation center, are listed in Supplementary Table 3 .
Statistical analyses
Data are expressed as mean ± standard error of the mean (SEM) unless otherwise noted. Data were analyzed as appropriate for the experimental design and as indicated in the text and figure legends. In most cases, P-values are reported independent of a statement regarding statistical significance. All of the results of our statistical analyses can be found in table format, and any relationships specifically highlighted in the text as being positively or negatively correlated are also provided in figure format. Statistical analyses were performed with GraphPad Prism version 8 (GraphPad Software, San Diego, CA).
Results
Islet preparations used in gene expression and insulin secretion assays
Donor Demographics
The gene expression analyses performed in this work used islets isolated from a panel of 80 organ donors spanning a BMI range of approximately 19-45 (See Supplementary Tables 1 and  2 ). The BMI panel consists of two separate sets of samples: Set 1 was collected from 2011 to 2013 and includes 40 individuals with a BMI of 19-41.3, while Set 2 was collected from 2013-2015 and consists of 40 individuals with a BMI of 22.8-44.7. The two islet sets were wellmatched for donor age BMI (Table 1: P=0.67 and 0.47, respectively, by two-tailed t-test), as well as gender distribution (Set 1: N=15 female donors and N=25 male donors; Set 2: N=13 female donors and 27 male donors). Thirteen of 80 islet preparations were from lean donors (BMI < 25), with no donors being underweight (BMI < 18.5); 21 were from overweight donors (BMI 25-29.9); and 46 were from obese donors, with only 6 classified as high-risk (morbid) obesity (BMI ≥ 40). This BMI distribution suggests our panel as a good representation of the normal physiological changes islets are exposed to during the progression from lean to overweight to obesity in both sexes.
Genes probed in Islet cDNA Set 1 and Set 2
For qPCR assays, not all genes were tested in both sets, and not every gene was tested in each cDNA sample. Genes unique to Set 1 include adenylate cyclase 1 (ADCY1), ADCY5, ADCY6, glucokinase (GCK), pyruvate kinase M1/M2 (PKM), and cyclin A1 (CCNA1). Genes unique to Set 2 include prostaglandin E synthase 3 (PTGES3), Gαz (GNAZ), and interleukin 6 (IL6). Prostaglandin EP3 receptor (PTGER3), COX-1 (PTGS1) (officially known as prostaglandinendoperoxidase synthase 1: PTGS1), COX-2 (PTGS2) (officially known as PGTS2), PTGES, and PTGES2 were probed in both sets. A table of qPCR primer sequences can be found in Table 2 .
Preparations used for insulin secretion assays
Functional assays in response to 1.7 mM glucose and 16.7 mM glucose, with and without the addition of the GLP1R agonist, exendin-4 (10 nM) or the EP3 antagonist, L798,106 (10 µM), were performed on 22 islet preparations from Set 2 of the BMI panel, as indicated in Supplemental Table 2 .
Gene/BMI correlations
Overview of analytical methods
We determined the relationship between donor BMI and gene expression using two methods:
(1) linear curve-fit analysis and (2) binning samples by donor obesity status (BMI < 30 and BMI ≥ 30; N=17 non-obese and N=23 obese donors in each set) and performing a two-tail T-test. The complete results of this analysis can be found in Supplementary Table 4 . Table 4 ). Among the genes in the PGE2 production pathway tested (PTGS1, PTGS2, PTGES, PTGES2, and PTGES3), PTGES2 and PTGES3 had no apparent relationship with BMI (Supplementary Table 4 ). PTGS1 had a weak linear relationship with BMI (p=0.0854, R 2 =0.05397); PTGS2 had a weak linear relationship with BMI (p=0.043, R 2 =0.0634) and a stronger, positive association with obesity status (p=0.0601); and PTGES had a weak linear relationship with BMI (p=0.0733, R 2 =0.04925) ( Figure 1A -C). GNAZ expression was not correlated with BMI in either analysis (Supplementary Table 4 ). In contrast, mRNA levels of all three of the Gαz-sensitive adenylate cyclase isoforms-ADCY1, ADCY5, and ADCY6-had positive, linear relationships with donor BMI (ADCY1, p=0.0176, R 2 =0.2749; ADCY5, p=0.0135, R 2 =0.294; ADCY6, p=0.0094; R 2 =0.371); a relationship that, for the most part, also held true when samples were binned by obesity status (p=0.0706, p=0.0380, and p=0.0768, respectively) ( Figure 1D -F).
Genes involved in the PGE2 production and EP3/Gαz signaling pathways PTGER3 expression was not correlated with BMI in either analysis (Supplementary
Genes involved in beta-cell compensation
We determined the relative mRNA abundance of proteins important in the adaptive metabolic (GCK, PKM), proliferative (CCNA1), and survival (IL6) response(s) to obesity and insulin resistance as related to donor BMI. Of these, GCK and IL6 had positive linear relationships with BMI (GCK, p=0.0010, R 2 =0.549; and IL6, p=0.0263; R 2 =0.1233), and the mean expression of GCK and IL6 were elevated in islets from obese donors as compared to lean/overweight (p=0.0081 and p=0.0129, respectively) ( Figure 1G ,H). CCNA1 and PKM had no apparent relationship with obesity in either analysis ( Supplementary Table 4 )
Gene/gene correlations
Overview of analytical methods
As with gene/BMI correlations, we determined the relationship between the expression of two genes by linear curve-fit analysis. The complete results of this analysis can be found in Supplementary Table 5 .
Genes involved in the EP3/Gα z signaling and PGE2 production pathways
We plotted the expression of PTGER3, ADCY1, ADCY5, ADCY6, PTGS1, PTGS2, PTGES, PTGES2, PTGES3, and GNAZ against each other. All of the genes in the EP3/Gαz signaling pathway had one or more relationships with each other, with PTGER3 being related to nearly all of the others (PTGER3 vs. GNAZ, p=0.0089, R 2 =0.1751; PTGER3 vs. ADCY1, p=0.0278, R 2 =0.2016; PTGER3 vs. ADCY5, p=0.0106, R 2 =0.2618; ADCY1 vs. ADCY5, p=0.0002, R 2 =0.4617; ADCY5 vs. ADCY6, p=0.0111, R 2 =0.2942) (Figure 2A -E).
As with the expression genes in the EP3/Gαz signaling pathway, those in PGE2 production pathway were also highly correlated with each other (PTGS1 vs. PTGES, p=0.0012, R 2 =0.1982; PTGS1 vs. PTGES2, p=0.0504, R 2 =0.0807; PTGES vs. PTGS2, p=0.0093, R 2 =0.1076; PTGES vs. PTGES2, p=0.0008, R 2 =0.1733; PTGES2 vs. PTGES3, p=0.0652, R 2 =0.0938) ( Figure 2F -J).
PTGER3 and GNAZ were the only genes that bridged the two pathway groups, with PTGER3 being related to PTGS1 and PTGES3 (p=0.0295, R 2 =0.0805 and p=0.0103, R 2 =0.1638, respectively), and GNAZ being related to PTGS1 (p=0.0123, R 2 =0.1661) ( Figure 2K -M). Figure 2N shows a model of the relationships between the genes in the EP3/Gαz signaling pathway and PGE2 production pathway, with two clusters clearly evident. As ADCY1, ADCY5, and ADCY6 were only probed in Set 1, and GNAZ and PTGES3 only in Set 2, it is possible more intra-or intercluster connections exist.
Genes involved in beta-cell compensation CCNA1
, GCK, and PKM expression were all positively correlated with each other (CCNA1 vs. GCK, p=0.0075, R 2 =0.294; CCNA1 vs. PKM, p=0.0847, R 2 =0.1413; GCK vs. PKM, p=0.0222, R 2 =0.2461) ( Table 1) . As IL6 was only probed in Set 2, its relationship with the others was not determined.
Of the genes in the EP3/Gαz signaling pathway and PGE2 production pathway, only those involved in EP3/Gαz signaling were correlated with CCNA1 (PTGER3, p=0.04, R 2 =0.1781; ADCY1, p=0.0154, R 2 =0.2487; ADCY5, p=0.0591, R 2 =0.1594) ( Figure 3A -C). ADCY6 had a weak positive, linear correlation with CCNA1 (p=0.097, R 2 =0.137) ( Supplementary Table 5 ). PTGER3, ADCY1, ADCY5, and ADCY6 were also the only genes correlated with GCK, with all four being positively associated (PTGER3, p=0.0003, R 2 =0.4481; ADCY1, p=0.0003, R 2 =0.4422; ADCY5, p=0.0005, R 2 =0.4165; and ADCY6, p=0.0288, R 2 =0.2275) ( Figure 3D -G). PTGER3 was also positively associated with PKM (PTGER3, p=0.0016, R 2 =0.399) ( Figure 3H ). In contrast, none of the genes in the PGE2 production pathway were correlated with CCNA1, GCK, or PKM expression ( Supplementary Table 5 ), save a negative correlation between PTGES expression and PKM (p=0.0226, R 2 =0.3894) ( Figure 3I ). In contrast, all genes involved in the PGE2 production pathway, save PTGES3, were positively correlated with IL6 expression (PTGS1, p=0.0057, R 2 =0.1999; PTGS2, p=0.0009, R 2 =0.2823; PTGES, p=0.0067, R 2 =0.1873; and PTGES2, p=0.0395, R 2 =0.1126) ( Figure 3K -M). Neither PTGER3 nor GNAZ was correlated with IL6 expression (Supplementary Table 5 ). These results suggest PGE2 production and signaling through EP3/Gαz both influence beta-cell adaptation to obesity and insulin resistance through at least partially divergent mechanisms. Figure 3N shows a model of the relationships between the genes in the EP3/Gαz signaling pathway and PGE2 production pathway with those involved in beta-cell compensation. As with the EP3/Gαz signaling and PGE2 production pathway correlations shown in Figure 2N , two clusters were clearly evident. As CCNA1, GCK, PKM, ADCY1, ADCY5, and ADCY6 were only probed in Set 1, and IL6, GNAZ and PTGES3 only in Set 2, it is possible more intra-or inter-cluster connections exist.
Gene/islet insulin content and beta-cell function correlations
Overview of experimental design and analytical methods
For about half of the islet preparations represented in our latter BMI panel (22 of 40), we performed static GSIS assays in 1.7 mM glucose, 16.7 mM glucose, 16.7 mM glucose + 10 nM exendin-4 (Ex4: a GLP1R agonist), 16.7 mM glucose + 10 µM L798,106 (L798: a specific EP3 antagonist), and 16.7 mM glucose + Ex4 + L798. Therefore, we are able to plot BMI or relative expression of the eight genes probed in that panel (PTGER3, GNAZ, PTGS1, PTGS2, PTGES, PTGES2, PTGES3 and Il6) with measurements of beta-cell mass and function: (1) islet insulin content; (2) glucose-stimulated insulin secreted (GSIS); (3) GSIS as a percent of islet insulin content (GSIS%); (4) secretion index (SI), or the ratio of GSIS in 16.7 mM glucose over that in 1.7 mM glucose; (5) incretin response (IR), or the ratio of GSIS in 16.7 mM glucose + Ex4 over than in 16.7 mM glucose alone; (6) L798 SI, or the ratio of GSIS in 16.7 mM glucose + L798 over that in 16.7 mM glucose alone; and (7) L798 IR, or the ratio of GSIS in 16.7 mM glucose + Ex4 + L788,106 over that in 16.7 mM glucose + Ex4. The complete results of this analysis can be found in Supplementary Table 6 .
Quality-control measurements and population-based analyses of human islet functional response
Beta-cell function can be compromised in cultured, shipped islets. A Wilcoxon signed-rank test revealed the median SI of the entire islet population (5.90) deviated significantly from 1 (p<0.0001), indicating overall good glucose responsiveness in the majority of islet preparations ( Figure 4A ). The median IR of all islet preparations (1.27) deviated significantly from 1 (p<0.0001), indicating intact GLP1R signaling in the majority of islet preparations ( Figure 4B , left). Because of their opposing effects on cAMP production, agonists of GLP1R and antagonists of EP3 should have additive, positive effects on SI, presuming that agonist-sensitive EP3 isoforms are expressed and are being stimulated by endogenous PGE2. The median L798 SI (0.98) was not significantly different from 1 (p=0.6333) ( Figure 4B , middle), indicating weak endogenous agonist-dependent EP3 signaling in these islets, as expected based on previous work [1]. The median L798 IR (1.14) did deviate significantly from 1 (p=0.0071) ( Figure 4B right), revealing, in the majority of islet preparations, L798,106 treatment ameliorated an (albeit small) inhibitory constraint on cAMP-mediated GLP1R signaling. This result was only revealed by considering the distribution of L798 IR of the entire islet population, as the L798 IR of each islet preparation was not significantly different from baseline IR (data not shown), consistent with our previously-published results using a smaller set of human islet preparations [1].
Relationship of donor BMI with islet insulin content and beta-cell function
BMI was positively correlated with islet insulin content (p=0.0042, R 2 =0.3415) ( Figure 5A) Table 6 ). GSIS% was unaffected by BMI, though ( Supplementary Table 6 ), indicating islets from higher BMI donors secrete more insulin simply because they have more insulin to secrete. A weak, negative correlation of BMI with GSIS% in 1.7 mM glucose (p=0.0839; R 2 =0.1419) suggests possible beta-cell dysfunction in islets from donors with higher BMI (Supplementary Table 6 ). BMI also had a weak negative correlation with IR (p=0.1219, R 2 = 0.1154), but not with other measurements of islet responsivity to any other treatment (SI, L798 SI, and L798 IR) (Supplementary Table 6 ).
Relationship of PTGER3 and GNAZ expression with islet insulin content and beta-cell function
PTGER3 expression had no relationship with islet insulin content, GSIS, GSIS% in 1.7 mM or 16.7 mM glucose, SI, IR, L798 SI, or L798 IR (Supplementary Table 6 ). On the other hand, GSIS% in 16.7 mM glucose, with or without the addition or Ex4, was enhanced with L798,106 cotreatment (16.7G + L798: p=0.0673, R 2 =0.1654; 16.7G + Ex4 + L798; p=0.0694, R 2 =0.1632) ( Figure 5B ,C). These results are consistent with the expected effect of an EP3 antagonist on GSIS% if agonist-sensitive EP3 variants are being stimulated by endogenous PGE2 [1].
GNAZ expression was negatively correlated with islet insulin content (p=0.054; R 2 =0.1732) ( Figure 5D ). A negative relationship of GNAZ expression on insulin content was reflected in a negative influence on GSIS in 1.7 mM glucose, 16.7 mM glucose, and 16.7 mM glucose + Ex4, although these relationships were overall weak (Supplementary Table 6 ). GNAZ expression did not impact GSIS% in any treatment condition, including with the addition of L798,106, SI, IR, L798 SI, or L798 IR (Supplementary Table 6 ). In comparison to the results described above for PTGER3, these results suggest any reduction of GSIS by increased GNAZ expression is primarily driven by decreased insulin content and not by an influence of PGE2-mediated EP3 signaling.
PTGS2 expression, and not that of other genes in the PGE2 production pathway, is positively correlated with islet insulin content and secretory capacity
Like BMI, PTGS2 expression was positively correlated with higher islet insulin content (p=0.0004; R 2 =0.4689) ( Figure 5E ) and total insulin secreted in all conditions ( Table 6 ). Unlike BMI, PTGS2 expression did not influence GSIS% in 1.7 mM glucose or IR ( Supplementary Table 6 ), suggesting PTGS2 expression alone does not promote beta-cell dysfunction. None of the other genes in the PGE2 synthetic pathway (PTGS1, PTGES, PTGES2, and PTGES3) had any significant impact on islet insulin content, GSIS, GSIS%, SI, IR, L798 SI, or L798 IR (Supplementary Table 6 ). These results support the key role of COX-2 as the rate-limiting enzyme in PGE2 production, with the expression of other enzymes-all being upregulated by the same inflammatory conditions that induce PTGS2 expression-being non-ratelimiting.
Exclusion of selection bias in IL6 and PTGS2 GSIS assays.
In the full set of islet preparations comprising Set 2, IL6 expression was positively correlated with BMI (with PTGS2 more weakly so), and IL6 and PTGS2 expression were highly correlated with each other. Yet, only BMI and PTGS2 expression were positive predictors of islet insulin content: IL6 expression had no relationship with islet insulin content or any measurements of beta-cell function ( Supplementary Table 6 ). In order to exclude selection bias in these divergent results, we limited our gene expression analyses to only those of the 22 islet preparations used in GSIS assays, and found the same relationships(s), albeit weaker, as when the full set was used (IL6 vs. BMI linear curve-fit: p=0.1137, R 2 =0.1204; IL6 by obesity status: p=0.1048; PTGS2 vs. BMI linear curve-fit: p=0.2028, R 2 =0.07997; PTGS2 by obesity status: p=0.1626; IL6 vs. PTGS2: p=0.179; R 2 =0.2494) ( Figure 6A -E).
Gαz over-expression in human donor islets and effects on islet insulin content and GSIS.
Overview of experimental design and analytical methods
When islets are isolated from T2D human organ donors, tonic activation of EP3 by PGE2 blunts the ability of the beta-cells to secrete insulin in response to glucose: a phenotype that can be at least partially ameliorated by the EP3 antagonist, L798,106. To explore the hypothesis that increased Gαz activity in the T2D state is responsible for defects in beta-cell function, we transduced islets from three human donors with an adenovirus bicistronically encoding GFP and human Gαz, or a GFP control adenovirus, and cultured islets for two days prior to GSIS assays. Two independent pools of islets from each donor were used, providing 6 biological replicates total. After two days in culture, GFP expression was clearly evident by fluorescence microscopy ( Figure 7A ), and qPCR confirmed GNAZ overexpression (ACTB Ct, ~21 for all preparations; GNAZ Ct ~24, GFP-infected vs. Ct ~15-18, Gαz-infected; data not shown). With GNAZ Ct values outside of the linear range of the assay, the degree of overexpression was not quantified. All islet insulin content and GSIS results were normalized to those of the mean of the GFP control to account for (1) intrinsic differences in total islet insulin content and GSIS% among the three islet preparations and (2) the effect of adenoviral transduction itself. The raw GSIS data can be found in Supplementary Figure 1 .
Gαz over-expression in human donor islets mimics the beta-cell dysfunction of T2D.
After two days in culture, the mean insulin content was 36% lower in Gαz-transduced islets as compared to GFP control (GFP, 0.9999 ± 0.04628, vs. Gαz 0.6438 ± 0.05973; p = 0.008) ( Figure  7B ). Furthermore, while GSIS% in 1.7 mM glucose was unchanged in Gαz-transduced islets as compared to GFP control, GSIS% in 16.7 mM glucose was 39% lower (1.00 ± 0.03063, GFP vs. 0.6127± 0.08711, Gαz; p = 0.0018), and the mean stimulation index was 40% lower (3.479 ± 0.1669, GFP vs. 2.009 ± 0.2783, Gαz; p = 0.0017) ( Figure 7C ,D).
Discussion
Insulin resistance, often found with obesity, necessitates the hyperproduction and processing of proinsulin into mature insulin in order to augment insulin secretory capacity, causing significant mitochondrial oxidative and ER stress [8] [9] [10] . Insulin resistance also causes a host of physiological changes-including, but not limited to, mild hyperglycemia, hyperinsulinemia, hyperglucagonemia, dyslipidemia, and systemic inflammation. All of these factors impact the beta-cell, and, depending on whether the exposure is acute or chronic, have differential effects on downstream adaptive vs. terminal biological processes. In a compensating beta-cell, mitochondrial and ER stress are ameliorated by cell signaling pathways such as the adaptive unfolded protein response (UPR) and autophagy, which allow the beta-cell to continue to function at a high level. Beta-cell proliferation is stimulated by cell autonomous and nonautonomous factors, allowing for increased beta-cell mass. So long as the beta-cell is able to continue to adapt, T2D will not occur. Yet, many of the factors linked with beta-cell adaptation in the obese & insulin resistant state(s) have also been proposed as contributing to the development and/or pathophysiology of T2D itself, including in our own previously-published work on PGE2 production and EP3 signaling [1] . In this work, we have defined a potential mechanism of beta-cell compensation characterized by islet mRNA expression of PTGS2/COX-2, the rate-limiting enzyme for PGE2 production, in islets collected from a panel of non-diabetic human organ donors. In this study, enhanced PTGS2 expression occurs in the absence of either enhanced islet PTGER3 expression or strong effects of an EP3 antagonist on the insulin secretion response. Instead, PTGS2 expression is directly correlated with islet insulin content. In other words, the amount of insulin secreted from islets of non-diabetic human donors in all conditions tested is proportional with their PTGS2 expression, while insulin secretion as normalized to percent of content is unchanged: donor islets with higher PTGS2 expression secrete more insulin because they have more to secrete. These results identify PGE2 (and/or possibly other PTGS2/COX-2 metabolites) as important factors in the maintenance or augmentation of functional beta-cell mass. Consistent with our previously-published work [2] , we also found evidence for signaling mechanisms downstream of the EP3-associated Gαz that may regulate beta-cell mass, albeit in an agonist-independent manner.
COX-1 and COX-2 (officially known as prostaglandin-endoperoxidase 1 and 2: PTGS1 and PTGS2), catalyze the rate-limiting step in the production of PGE2 derived from arachidonic acid (AA) incorporated in plasma membrane phospholipids. High glucose, free fatty acids, and/or pro-inflammatory cytokines have all been shown to upregulate the expression and/or activity of enzymes involved in the PGE2 synthetic pathway, including phospholipase A2 (PLA2: which cleaves AA from membrane phospholipids); COX-1 and COX-2 (which convert arachidonic acid to the intermediate, PGH2); and PTGES, PTGES2, and PTGES3, which convert PGH2 to PGE2 [1, [11] [12] [13] [14] [15] [16] . Using BMI as a marker of obesity/insulin resistance, we found a weak correlation with PTGS2 expression ( Figure 1B) , consistent with results of a previous study [1] . Yet, BMI is a flawed surrogate for both obesity and insulin resistance. While there exists controversy in the literature, recent reports support IL-6 as an "anti-inflammatory" cytokine that promotes betacell adaptation. IL-6 is required for the adaptive proliferative response to HFD-induced glucolipotoxicity by paracrine effects on the alpha-cell [17] . IL-6 was also recently identified as mediating beta-cell autophagy-a survival mechanism working in concert with the adaptive UPR-through stimulation of alpha-cell GLP-1 production [18] . IL-6 expression has also been specifically linked with PGE2 produced by COX-2 and not COX-1, which is of particular relevance to the beta-cell, as, in contrast to nearly all other cell types, beta-cell COX-2 expression is constitutive. Although COX-2 can be further induced by various stimuli, COX-2 is the major isoform responsible for both endogenous and stimulated beta-cell PGE2 production [15, 16, 19, 20 ]. In the current work, in non-diabetic human organ donors, PTGS2 expression was strongly correlated with IL-6 mRNA expression ( Figure 3K ). Coupled with the relationship between PTGS2 expression and islet insulin content ( Figure 5E ), this result provides more evidence for increased COX-2 abundance as a critical component of the beta-cell adaptive response. A limitation of the current work is that we did not directly measure islet PGE2 secretion or confirm COX-2 protein levels by Western blot. Yet, in previous work with islets from non-diabetic and T2D human organ donors, the difference in relative PTGS2 expression determined by qPCR (~6fold) was well-matched to the fold-change in total PGE2 released per islet during an overnight culture period (~4.5-fold) [11] . Therefore, we believe PTGS2 expression is an acceptable surrogate marker for islet PGE2 production rate.
Beta-cell stress can also be elicited by islet cell non-autonomous mechanisms that can build off of each other in a feed-forward mechanism to promote beta-cell dysfunction and, ultimately, loss of functional beta-cell mass. The systemic inflammation coincident with the insulin resistance of obesity further promotes mitochondrial and ER stress in already stressed betacells by the secretion of pro-inflammatory cytokines from insulin-resistant, M1-polarized macrophages resident within the islet itself, ultimately attracting cytotoxic immune cells and causing beta-cell demise [17, 21, 22] . Resident islet macrophages also have critical roles in betacell adaptation and failure. Addition of PGE2 to macrophages induces low-level IL-6 expression and promotes the polarization of macrophages to the M2 state [21] and prevents proinflammatory cytokine secretion by lipopolysaccharide-activated M1 macrophages [23]. In cancer cells, COX-2-mediated PGE2 production suppresses the expression of tumor cell chemokines required for the recruitment of cytotoxic immune cells [23] . Taken together, COX-2-mediated PGE2 production and IL-6 expression/secretion by both beta-cells and islet immune cells coordinate to elicit multiple beneficial and overlapping effects on beta-cell function and survival, including through other possible mechanisms not discussed here.
PGE2 is the most abundant natural ligand for the EP3 receptor (encoded by the PTGER3 gene). Unless islets are isolated from human organ that are frankly T2D, islet PTGER3 mRNA expression is minimally changed [1, 24] . Islets isolated from non-diabetic human organ donors have little-to-no functional, proliferative, or survival response to either EP3 agonists or antagonists unless islets have been cultured in glucolipotoxic, pro-inflammatory, or other stress conditions [1, 24, 25] . We have previously published or contributed to two studies characterizing PTGER3 expression in human islet cDNA samples from non-diabetic human organ donors of varying BMI, with seemingly disparate results. In Kimple and colleagues, when islets were binned by obesity status, PTGER3 expression was significantly correlated with donor BMI [1]. In the current study, PTGER3 expression was not correlated with the BMI of the donor, whether linearly or by binning islets by obesity status (Supplementary Table 4 ). A lack of linear correlation of PTGER3 expression in the current study with the BMI of non-diabetic donors is consistent with the findings of Carboneau and colleagues [24] . In our experience using mouse models of glucose intolerance and T2D, as well as islets isolated from T2D human organ donors as compared to non-diabetic donors, EP3 mRNA abundance changes of 100-fold or more from the non-diabetic state predict islet responsiveness to EP3 agonists and antagonists [1] . As the mean difference in PTGER3 expression by obesity status in Kimple and colleagues was relatively small (ΔΔCt ≈ 1.5; fold-change ≈ 2.8), it is likely this change is of limited biological relevance, regardless of statistical significance. Support for this concept is the lack of a potentiating effect of L798,106 on GSIS as donors become increasingly obese ( Figure 4B and Supplementary Table  6 ). Yet, as expected, islets with higher PTGER3 expression tended to have increased GSIS% in stimulatory glucose with and without Ex-4 when L798,106 was included, although this effect was weak and was only brought out by a population-based analysis ( Figure 4B and Figure 5B ,C).
In the beta-cell, EP3 is specifically coupled to the inhibitory G protein α-subunit, Gαz. Gαz is a classical inhibitory Gαi/o subunit, negatively regulating the production of cAMP by adenylate cyclase (AC). Of all the Gαi/o subfamily members, Gαz is the most disparate, both at the primary sequence level and with regards to its biochemical properties. The GTP hydrolysis (i.e., inactivation) rate of Gαz is incredibly slow (t1/2 ≈ 10 min) [26, 27] . Therefore, Gαz has the potential to elicit partial tonic inhibition AC-mediated cAMP production: a well-known contributor to beta-cell function, replication and survival. There are 10 distinct AC isoforms, but in vivo Gαz activity has only been demonstrated towards AC1 and AC5, with activity towards AC6 (closely related to AC5) being shown in vitro [28] . In this work, ADCY1, ADCY5, and ADCY6 expression were all positively correlated with donor BMI and CCNA1 expression ( Figure 1D -F, Figure 2D ,E and Tables 3 and 4 ), suggesting their importance in the beta-cell compensatory response-a theory also supported in the literature [29] [30] [31] [32] [33] . In this work, Gαz expression in islets from non-diabetic human organ donors was correlated with decreased islet insulin content ( Figure 5D ), with no impact on GSIS% ( Supplementary Table 6 ). In a study of wild-type and Gαz-null C57BL/6N mice, extended feeding of a 45 kcal% HFD-a strong model of beta-cell compensation for insulin resistance-Gαz loss synergized with HFD feeding to promote increased beta-cell replication, significantly augmenting beta-cell mass, with no effects on GSIS% [2] . These latter results are fully consistent with our findings on the relationship between GNAZ expression and islet insulin content and GSIS% in islets isolated from non-diabetic human organ donors. As we did not directly quantify replication in this study, though, we cannot confirm that increased islet insulin content is due to increased beta-cell mass and not increased insulin content of individual beta-cells, nor can we confirm putative changes in beta-cell mass are due to replication and not survival. Furthermore, as the mRNA expression of Gαz-sensitive AC isoforms was only quantified in Set 1 of our human islet panel, and Gαz mRNA expression only in Set 2, we cannot directly compare the relationship of ADCY1, ADCY5, ADCY6, and GNAZ expression with the full panel of markers of beta-cell compensation, nor can we determine the correlation of ADCY1, ADCY5, and ADCY6 expression with islet insulin content or measurements of beta-cell function.
The decreased insulin content (if representative of beta-cell mass) in Gαz overexpressing islets ( Figure 7B ) would appear as direct support for an effect of Gαz signaling on human beta-cell proliferation. Yet, as the replication rate of isolated human pancreatic islets is quite low, it is more likely these results are due to a negative effect of Gαz on beta-cell survival. In the INS-1 (832/13) and (832/3) rat insulinoma cell lines, adenoviral overexpression of wild-type human Gαz significantly reduced cAMP production and total cell number after a 2-3-day culture, synergizing with streptozotocin or IL-1β to promote beta-cell apoptosis [4] . Furthermore, in models of T1D, islets from Gαz null mice had significantly fewer TUNEL-positive beta-cells, in addition to a significantly enhanced beta-cell proliferation rate and functional response to glucose and Ex4 [4, 5] . Yet, in the context of HFD-feeding, even wild-type islets from HFD-fed mice had few-to-no TUNEL-positive beta-cells, with the effects of Gαz loss being attributed solely to effects on beta-cell replication ( [2] and M.E.K., unpublished data). Effects of Gαz activity on proliferation in the beta-cell highly compensating for insulin resistance and survival in the context of terminal diabetes, particularly when PGE2/EP3/Gαz signaling is dysfunctionally up-regulated, are not discordant.
While GNAZ expression was negatively correlated with human islet insulin content ( Figure 5D ), PTGER3 expression was not (Supplementary Table 6 ), even though gene expression of the ratelimiting enzymes for PGE2 production, COX-1 and COX-2, were positively correlated with both donor BMI and IL6 expression ( Figure 1A ,B and Figure 3J ,K); the latter a surrogate marker for the beta-cell compensatory state. In fact, PTGER3 expression was positively correlated with CCNA1 expression ( Figure 3A) , supporting, if anything, increased beta-cell replication with increased EP3 expression in non-diabetic human donor islets. There are several non-mutuallyexclusive explanations for this discrepancy. First, while heterotrimeric G proteins are traditionally thought of as being activated by ligand binding to their associated receptor, receptor-independent mechanisms have been described [34-36], although none specifically for Gαz. Second, in all species characterized, the PTGER3 gene encodes multiple splice variants differing only in their C-terminal tails: critical determinants of G protein coupling, desensitization, and constitutive activity. The mouse Ptger3 gene encodes three splice variants (EP3α, EPβ, and EP3ɣ) that have been much more widely characterized than the human splice variants. EP3α and EP3ɣ have partial to nearly-full constitutive activity, respectively, against Gi/o subfamily members [14, 37] . EP3ɣ expression has been shown to be up-regulated in aged mouse islets, while islets from aged Gαz-null mice have enhanced beta-cell proliferation and function, supporting EP3ɣ/Gαz signaling as contributing to the mild glucose intolerance of aging [2, 24] . The human PTGER3 gene encodes 12 known mRNA splice variants (with 4 additional variants being computationally mapped), producing 12 proteins with distinct C-terminal sequences. Of the mouse isoforms, both EP3α and EP3ɣ have human homologs-EP3I (a.k.a. variant 4) and EP3II (a.k.a. variant 5): the most highly-abundant human EP3 splice variants [14, 38] . Due to the complexity of PTGER3 splicing and overlapping ORFs in the human genome, we quantified only total PTGER3 expression. Yet, differences in the relative expression of agonist-sensitive vs. constitutively-active human EP3 splice variants in the healthy vs. compensating beta-cell could explain how changes in Gαz expression could modulate beta-cell mass in an agonistindependent manner without corresponding changes in overall PTGER3 gene expression. Finally, Gαz is unique in that, its GTP-bound state, it can bind to Rap1GAP [39, 40], a negative regulator of the small G protein, Rap1. Rap1 is well-known as a contributor to the cAMPmediated amplification pathway of GSIS, but has also been well-characterized as an oncogene [41] , and previous work from our laboratory has implicated cAMP-mediated Rap1 activity in a non-canonical mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway that promotes beta-cell replication [42] . Interestingly, binding of Gαz to Rap1GAP and adenylate cyclase are mutually-exclusive [40] . Furthermore, cAMP-, insulin-and inflammation-mediated signaling mechanisms that are prominent in the beta-cell highly compensating for insulin resistance all have been shown to result in post-translational modifications of Gαz, Rap1GAP, and Rap1 that impact protein activity and effector preference [43] [44] [45] [46] [47] [48] [49] . Of note, when Rap1GAP is phosphorylated by PKA, it is ineffective to catalyze the GTP hydrolysis of Rap1 [46] . Our primary working hypotheses is that, unless PGE2 production and EP3 expression are dysfunctionally up-regulated in human islets by the conditions of the T2D state (as described in previous work [1] and mimicked in this work by adenoviral overexpression of Gαz), PGE2 signaling through EP3 is a functional compensatory mechanism to sequester Gαz-GTP from negatively inhibiting AC by encouraging binding to a catalytically-inactive Rap1GAP. Confirming this latter "signaling switch" model is our current focus.
In conclusion, we have defined a putative EP3-independent beta-cell compensation mechanism mediated by IL-6 and COX-2 that may enhance functional beta-cell mass in the islet highly compensating for obesity, inflammation and insulin resistance. Furthermore, we have identified Gαz and its downstream AC targets as critical negative and positive regulators, respectively, of the human beta-cell compensatory response, potentially through regulation of beta-cell replication. The major limitation of our study is the primarily correlative nature between comparisons of BMI, gene expression, and biological outcomes. More work will be needed in order to confirm the importance of these signaling pathways in beta-cell compensation, as well as their specific cellular and molecular mechanisms. Yet, our islet studies are well-designed, rigorous, comprehensive, and our results considered in the context of a broad existing body of work, lending credence to the strength and interpretation of our results. Overall, the model(s) proposed in this manuscript are a significant step forward in synthesizing often disparate results describing the mechanisms behind human beta-cell compensation to obesity and insulin resistance, before the progression to overt T2D.
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Supplemental Figure 1 . Raw values for islet insulin content and GSIS% for three human islet preparations used in Figure 7 , either uninfected or transduced with GFP-or human Gαz-encoding adenoviruses. A, C, and E: Total islet insulin content for SAMN10977276, SAMN11157311, and SAMN11155033, respectively. B, D, and F: GSIS as a percent of content in 1.7 mM glucose and 16.7 mM glucose for SAMN10977276, SAMN11157311, and SAMN11155033, respectively. Islet data for each donor's unique identifier are listed in Supplementary  Table 3 . 
